Regeneron Pharmaceuticals, Inc.
REGN
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including mā¦ read more
Healthcare
Biotechnology
35 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$781.49
Price-1.48%
-$11.77
1Y
Price
Market Cap
$80.511b
Large
Price/Earnings 3y Avg5y Avg
17.1x
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.+38.8%
EBITDA Margin+30.2%
Net Profit Margin+7.8%
Free Cash Flow Margin+38.8%
EBITDA Margin+30.2%
Net Profit Margin+7.8%
Free Cash Flow MarginRevenue
$15.535b
+8.3%
1y CAGR+5.9%
3y CAGR+6.3%
5y CAGREarnings
$4.329b
-3.9%
1y CAGR+3.3%
3y CAGR+0.2%
5y CAGREPS
$40.43
-2.5%
1y CAGR+5.3%
3y CAGR+1.7%
5y CAGRBook Value
$31.711b
$41.730b
Assets$10.019b
Liabilities$1.987b
DebtDebt to Assets
4.8%
0.3x
Debt to EBITDAFree Cash Flow
$3.522b
-13.7%
1y CAGR-0.8%
3y CAGR-4.9%
5y CAGRNo items found.
Press Releases
Statements and updates from the company